cell therapies

Banner image with text: 'Stay informed with the latest IP news' and the following words listed: Insights, Interviews, Webinars.

Patenting Antibody and Cell Therapies – What to Do and What Not to Do

By Joanna Applequist, Louise Jonshammar, Niklas Mattsson | Posted on September 28, 2020

Antibody drugs and cell therapies are at the heart of new biotechnology science. Not only do they show great promise when it comes to curing disease and helping patients, but also in creating value and growth. Biotech companies need to protect their scientific results and the corresponding investments with strong and durable patents. This is...

Tags: antibodies, Biotechnology, cell therapies, EPO, Litigation, patents

Recent contributors

Anders Heebøll-Nielsen, Partner and European Patent Attorney, Copenhagen, Denmark

Anders Heebøll-Nielsen

Partner, European Patent Attorney, Certified Danish Patent Agent

Ashley Zhao, Partner and Attorney at Law, Beijing, China

Ashley Zhao

Partner, Attorney at Law, Business Area Manager

Monika Trombitas Andersson, Associate and Attorney at Law, Lund, Sweden

Monika Trombitas Andersson

Associate, Attorney at Law, European Trademark and Design Attorney

Emily Chamberlain, Senior Associate and Patents, Stockholm, Sweden

Emily Chamberlain

Senior Associate, Patents

Niklas Mattsson, Partner and European Patent Attorney, Stockholm, Sweden

Niklas Mattsson

Partner, European Patent Attorney, Authorised Swedish Patent Attorney, UPC Representative

Ai-Leen Lim, Partner and Attorney at Law, Hong Kong SAR

Ai-Leen Lim

Partner, Attorney at Law, Group Vice President